1
|
Sonochemical synthesis and biological evaluation of isoquinolin-1(2H)-one/isoindolin-1-one derivatives: Discovery of a positive ago-allosteric modulator (PAAM) of 5HT2CR. Bioorg Chem 2022; 129:106202. [DOI: 10.1016/j.bioorg.2022.106202] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2022] [Revised: 09/12/2022] [Accepted: 10/07/2022] [Indexed: 11/23/2022]
|
2
|
Reddy GS, Kamaraj R, Hossain KA, Kumar JS, Thirupataiah B, Medishetti R, Sushma Sri N, Misra P, Pal M. Amberlyst-15 catalysed synthesis of novel indole derivatives under ultrasound irradiation: Their evaluation as serotonin 5-HT 2C receptor agonists. Bioorg Chem 2021; 116:105380. [PMID: 34670330 DOI: 10.1016/j.bioorg.2021.105380] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2021] [Revised: 07/07/2021] [Accepted: 09/19/2021] [Indexed: 11/30/2022]
Abstract
A series of indole based novel Schiff bases was designed as potential agonists of 5-HT2C receptor that was supported by docking studies in silico. These compounds were synthesized via Amberlyst-15 catalysed condensation of an appropriate pyrazole based primary amine with the corresponding indole-3-aldehyde under ultrasound irradiation at ambient temperature. A number of target Schiff bases were obtained in good yields (77-87%) under mild conditions within 1 h. Notably, the methodology afforded the corresponding pyrazolo[4,3-d]pyrimidin-7(4H)-one derivatives when the primary amine was replaced by a secondary amine. Several Schiff bases showed agonist activity when tested against human 5-HT2C using luciferase assay in HEK293T cells in vitro. The SAR (Structure-Activity-Relationship) studies suggested that the imine moiety was more favorable over its cyclic form i.e. the corresponding pyrazolopyrimidinone ring. The Schiff bases 3b (EC50 1.8 nM) and 3i (EC50 5.7 nM) were identified as the most active compounds and were comparable with Lorcaserin (EC50 8.5 nM). Also like Lorcaserin, none of these compounds were found to be PAM of 5-HT2C. With ∼24 and ∼150 fold selectivity towards 5-HT2C over 5-HT2A and 5-HT2B respectively the compound 3i that reduced locomotor activity in zebrafish (Danio rerio) larvae model emerged as a promising hit molecule for further study.
Collapse
Affiliation(s)
- Gangireddy Sujeevan Reddy
- Dr Reddy's Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500 046, India; Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Madhav Nagar, Manipal 576 104, Karnataka, India
| | - Rajamanikkam Kamaraj
- Dr Reddy's Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500 046, India
| | - Kazi Amirul Hossain
- Department of Physical Chemistry, Gdansk University of Technology, ul. Narutowicza 11/12, 80-233 Gdansk, Poland
| | - Jetta Sandeep Kumar
- Dr Reddy's Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500 046, India; Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Madhav Nagar, Manipal 576 104, Karnataka, India
| | - B Thirupataiah
- Dr Reddy's Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500 046, India; Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Madhav Nagar, Manipal 576 104, Karnataka, India
| | - Raghavender Medishetti
- Dr Reddy's Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500 046, India; Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Madhav Nagar, Manipal 576 104, Karnataka, India
| | - N Sushma Sri
- Dr Reddy's Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500 046, India
| | - Parimal Misra
- Dr Reddy's Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500 046, India
| | - Manojit Pal
- Dr Reddy's Institute of Life Sciences, University of Hyderabad Campus, Gachibowli, Hyderabad 500 046, India.
| |
Collapse
|
3
|
da Silva AW, Ferreira MKA, Rebouças EL, Mendes FRS, Dos S Moura AL, de Menezes JESA, Marinho MM, Marinho ES, Santos HS, Teixeira AMR. Anxiolytic-like effect of natural product 2-hydroxy-3,4,6-trimethoxyacetophenone isolated from Croton anisodontus in adult zebrafish via serotonergic neuromodulation involvement of the 5-HT system. Naunyn Schmiedebergs Arch Pharmacol 2021; 394:2023-2032. [PMID: 34251503 DOI: 10.1007/s00210-021-02116-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2021] [Accepted: 06/22/2021] [Indexed: 10/20/2022]
Abstract
Benzodiazepines are highly effective in combating anxiety; however, they have considerable adverse effects, so it is important to discover new safe anxiolytic agents. This study was designed to investigate the effect of the natural product 2-hydroxy-3,4,6-trimethoxyacetophenone (HTMCX) on anxiety and seizure behavior in adult zebrafish and its possible mechanisms of action. The acute toxicity of 96 h of HTMCX was analyzed, and the open and light/dark field tests (n = 6 animals/group) were used to assess the anxiety behavior of animals treated with HTMCX. In addition, the mechanisms of action were investigated with antagonists of the GABAA, 5-HT receptors, and molecular anchorage study. Pentylenetetrazole (PTZ) was used to induce seizure by immersion. As a result, acetophenone HTMCX (1, 3 and 10 mg/kg; v.o.) was non-toxic and affected locomotor activity. The higher doses (3 and 10 mg/kg; v.o.) produced signs of anxiolytic action in the light/dark test, and this effect was reversed by the pizotifen (antagonist 5HTR1 and 5HTR2A/2C), having the potential to form a complex with 5HTR1B. However, the anxiolytic effect of HTMCX has not been abolished by flumazenil (antagonist GABAA), cyproheptadine (antagonist 5HTR2A), and granisetron (antagonist 5HTR3A/3B). Therefore, HTMCX demonstrated an anxiolytic effect, suggesting that the 5HTR1 and 5HTR2C receptors may be involved in the pharmacological performance of this acetophenone in the central nervous system.
Collapse
Affiliation(s)
- Antonio Wlisses da Silva
- Graduate Program in Biotechnology, Northeast Biotechnology Network, State University of Ceará, Fortaleza, CE, Brazil
| | - Maria Kueirislene A Ferreira
- Graduate Program in Natural Sciences, Natural Products Chemistry Laboratory, State University of Ceará, Fortaleza, CE, Brazil
| | - Emanuela L Rebouças
- Graduate Program in Biotechnology, Northeast Biotechnology Network, State University of Ceará, Fortaleza, CE, Brazil
| | - Francisco Rogenio S Mendes
- Graduate Program in Biological Chemistry, Department of Biological Chemistry, Regional University of Cariri, Crato, CE, Brasil
| | - Atilano Lucas Dos S Moura
- Graduate Program in Natural Sciences, Natural Products Chemistry Laboratory, State University of Ceará, Fortaleza, CE, Brazil
| | - Jane Eire S A de Menezes
- Graduate Program in Natural Sciences, Natural Products Chemistry Laboratory, State University of Ceará, Fortaleza, CE, Brazil
| | - Márcia Machado Marinho
- Faculty of Philosophy Dom Aureliano Matos, State University of Ceará, Limoeiro do Norte, CE, Brazil
| | - Emmanuel Silva Marinho
- Faculty of Philosophy Dom Aureliano Matos, State University of Ceará, Limoeiro do Norte, CE, Brazil
| | - Hélcio S Santos
- Graduate Program in Biotechnology, Northeast Biotechnology Network, State University of Ceará, Fortaleza, CE, Brazil.,Graduate Program in Natural Sciences, Natural Products Chemistry Laboratory, State University of Ceará, Fortaleza, CE, Brazil.,Graduate Program in Biological Chemistry, Department of Biological Chemistry, Regional University of Cariri, Crato, CE, Brasil.,Science and Technology Centre, Course of Chemistry, State University Vale do Acaraú, Sobral, CE, Brazil
| | - Alexandre M R Teixeira
- Graduate Program in Biotechnology, Northeast Biotechnology Network, State University of Ceará, Fortaleza, CE, Brazil. .,Graduate Program in Biological Chemistry, Department of Biological Chemistry, Regional University of Cariri, Crato, CE, Brasil.
| |
Collapse
|
4
|
Higgins GA, Fletcher PJ, Shanahan WR. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. Pharmacol Ther 2020; 205:107417. [DOI: 10.1016/j.pharmthera.2019.107417] [Citation(s) in RCA: 28] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Accepted: 09/30/2019] [Indexed: 12/17/2022]
|
5
|
Kacem S, Emondts M, Bordet A, Leitner W. Selective hydrogenation of fluorinated arenes using rhodium nanoparticles on molecularly modified silica. Catal Sci Technol 2020. [DOI: 10.1039/d0cy01716g] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Rh nanoparticles prepared on hydrophobic molecularly modified silica act as effective catalysts for the hydrogenation of fluoroarenes to fluorocyclohexane derivatives.
Collapse
Affiliation(s)
- Souha Kacem
- Max Planck Institute for Chemical Energy Conversion
- 45470 Mülheim an der Ruhr
- Germany
- Institut für Technische und Makromolekulare Chemie
- RWTH Aachen University
| | - Meike Emondts
- Institut für Technische und Makromolekulare Chemie
- RWTH Aachen University
- 52074 Aachen
- Germany
- DWI-Leibniz Institute for Interactive Materials
| | - Alexis Bordet
- Max Planck Institute for Chemical Energy Conversion
- 45470 Mülheim an der Ruhr
- Germany
| | - Walter Leitner
- Max Planck Institute for Chemical Energy Conversion
- 45470 Mülheim an der Ruhr
- Germany
- Institut für Technische und Makromolekulare Chemie
- RWTH Aachen University
| |
Collapse
|
6
|
Wild CT, Miszkiel JM, Wold EA, Soto CA, Ding C, Hartley RM, White MA, Anastasio NC, Cunningham KA, Zhou J. Design, Synthesis, and Characterization of 4-Undecylpiperidine-2-carboxamides as Positive Allosteric Modulators of the Serotonin (5-HT) 5-HT 2C Receptor. J Med Chem 2018; 62:288-305. [PMID: 29620897 DOI: 10.1021/acs.jmedchem.8b00401] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
An impaired signaling capacity of the serotonin (5-HT) 5-HT2C receptor (5-HT2CR) has been implicated in the neurobehavioral processes that promote relapse vulnerability in cocaine use disorder (CUD). Restoration of the diminished 5-HT2CR signaling through positive allosteric modulation presents a novel therapeutic approach. Several new molecules with the 4-alkylpiperidine-2-carboxamide scaffold were designed, synthesized, and pharmacologically evaluated, leading to the discovery of selective 5-HT2CR positive allosteric modulators (PAMs). Compound 16 (CYD-1-79) potentiated 5-HT-evoked intracellular calcium release in cells stably expressing the human 5-HT2CR but not the 5-HT2AR cells. A topographically distinct allosteric site was identified based on the newly solved 5-HT2CR structure. Compound 16 modulated 5-HT2CR-mediated spontaneous ambulation, partially substituted for the training dose of the 5-HT2CR agonist WAY163909, synergized with a low dose of WAY163909 to substitute fully for the stimulus effects of WAY163909, and attenuated relapse vulnerability as assessed in a rodent self-administration model, indicating its therapeutic promise for CUD.
Collapse
|
7
|
García-Cárceles J, Decara JM, Vázquez-Villa H, Rodríguez R, Codesido E, Cruces J, Brea J, Loza MI, Alén F, Botta J, McCormick PJ, Ballesteros JA, Benhamú B, Rodríguez de Fonseca F, López-Rodríguez ML. A Positive Allosteric Modulator of the Serotonin 5-HT 2C Receptor for Obesity. J Med Chem 2017; 60:9575-9584. [PMID: 29116785 DOI: 10.1021/acs.jmedchem.7b00994] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The 5-HT2CR agonist lorcaserin, clinically approved for the treatment of obesity, causes important side effects mainly related to subtype selectivity. In the search for 5-HT2CR allosteric modulators as safer antiobesity drugs, a chemical library from Vivia Biotech was screened using ExviTech platform. Structural modifications of identified hit VA240 in synthesized analogues 6-41 afforded compound 11 (N-[(1-benzyl-1H-indol-3-yl)methyl]pyridin-3-amine, VA012), which exhibited dose-dependent enhancement of serotonin efficacy, no significant off-target activities, and low binding competition with serotonin or other orthosteric ligands. PAM 11 was very active in feeding inhibition in rodents, an effect that was not related to the activation of 5-HT2AR. A combination of 11 with the SSRI sertraline increased the anorectic effect. Subchronic administration of 11 reduced food intake and body weight gain without causing CNS-related malaise. The behavior of compound 11 identified in this work supports the interest of a serotonin 5-HT2CR PAM as a promising therapeutic approach for obesity.
Collapse
Affiliation(s)
- Javier García-Cárceles
- Departamento de Química Orgánica I, Universidad Complutense de Madrid , E-28040 Madrid, Spain
| | - Juan M Decara
- Unidad de Gestión Clínica de Salud Mental, Instituto IBIMA, Hospital Regional Universitario , E-29010 Málaga, Spain
| | - Henar Vázquez-Villa
- Departamento de Química Orgánica I, Universidad Complutense de Madrid , E-28040 Madrid, Spain
| | | | | | | | - José Brea
- Biofarma Research Group, USEF Screening Platform, CIMUS, USC , E-15782 Santiago de Compostela, Spain
| | - María I Loza
- Biofarma Research Group, USEF Screening Platform, CIMUS, USC , E-15782 Santiago de Compostela, Spain
| | - Francisco Alén
- Unidad de Gestión Clínica de Salud Mental, Instituto IBIMA, Hospital Regional Universitario , E-29010 Málaga, Spain
| | - Joaquin Botta
- School of Pharmacy, University of East Anglia , NR4 7TJ Norwich, U.K
| | - Peter J McCormick
- School of Veterinary Medicine, University of Surrey , GU2 7XH Guildford, U.K
| | | | - Bellinda Benhamú
- Departamento de Química Orgánica I, Universidad Complutense de Madrid , E-28040 Madrid, Spain
| | | | - María L López-Rodríguez
- Departamento de Química Orgánica I, Universidad Complutense de Madrid , E-28040 Madrid, Spain
| |
Collapse
|
8
|
Higgins GA, Zeeb FD, Fletcher PJ. Role of impulsivity and reward in the anti-obesity actions of 5-HT 2C receptor agonists. J Psychopharmacol 2017; 31:1403-1418. [PMID: 29072522 DOI: 10.1177/0269881117735797] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The selective 5-HT2C receptor agonist lorcaserin entered clinical obesity trials with the prevalent view that satiety was a primary mechanism of action. Subsequent Phase II and III trials demonstrated efficacy in terms of weight loss, although the overall effect size (~3% placebo-corrected change) is considered modest. Lorcaserin has been approved by the FDA for the treatment of obesity with lifestyle modification, but since its introduction in 2013 its sales are in decline, probably due to its overall modest effect. However, in some individuals, lorcaserin has a much more clinically significant effect (i.e. >10% placebo-corrected change), although what common features, if any, define these high responders is presently unknown. In the present article we highlight the evidence that alternative mechanisms to satiety may contribute to the anti-obesity effect of lorcaserin, namely effects on constructs of primary and conditioned reward and impulsivity. This may better inform the clinical evaluation of lorcaserin (and any future 5-HT2C receptor agonists) to subgroups of obese subjects characterized by overeating due to maladaptive impulsivity and reward mechanisms. One such population might be individuals diagnosed with binge eating disorder.
Collapse
Affiliation(s)
- Guy A Higgins
- 1 InterVivo Solutions Inc., Toronto, Canada.,2 Department of Pharmacology & Toxicology, University of Toronto, Toronto, Canada
| | - Fiona D Zeeb
- 3 Centre for Addiction and Mental Health, Toronto, Canada.,4 Department of Psychology & Psychiatry, University of Toronto, Toronto, Canada
| | - Paul J Fletcher
- 3 Centre for Addiction and Mental Health, Toronto, Canada.,4 Department of Psychology & Psychiatry, University of Toronto, Toronto, Canada
| |
Collapse
|
9
|
Kim J, Moon BS, Lee BC, Lee HY, Kim HJ, Choo H, Pae AN, Cho YS, Min SJ. A Potential PET Radiotracer for the 5-HT2C Receptor: Synthesis and in Vivo Evaluation of 4-(3-[18F]fluorophenethoxy)pyrimidine. ACS Chem Neurosci 2017; 8:996-1003. [DOI: 10.1021/acschemneuro.6b00445] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
Affiliation(s)
- Juhyeon Kim
- Center for Neuro-Medicine, Korea Institute of Science and Technology (KIST), 5 Hwarangno 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea
- Department of Chemistry, Korea University, Seoul 02841, Republic of Korea
| | - Byung Seok Moon
- Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea
| | - Byung Chul Lee
- Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea
| | - Ho-Young Lee
- Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea
| | - Hak-Joong Kim
- Department of Chemistry, Korea University, Seoul 02841, Republic of Korea
| | - Hyunah Choo
- Center for Neuro-Medicine, Korea Institute of Science and Technology (KIST), 5 Hwarangno 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea
- Department of Biological Chemistry, Korea University of Science and Technology (UST), 217 Gajungro, Yuseong-gu, Daejeon 34113, Republic of Korea
| | - Ae Nim Pae
- Department of Biological Chemistry, Korea University of Science and Technology (UST), 217 Gajungro, Yuseong-gu, Daejeon 34113, Republic of Korea
- Convergence Research Center for Diagnosis,
Treatment and Care System of Dementia, KIST, Seoul 02792, Republic of Korea
| | - Yong Seo Cho
- Center for Neuro-Medicine, Korea Institute of Science and Technology (KIST), 5 Hwarangno 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea
- Department of Biological Chemistry, Korea University of Science and Technology (UST), 217 Gajungro, Yuseong-gu, Daejeon 34113, Republic of Korea
| | - Sun-Joon Min
- Department of Chemical & Molecular Engineering/Applied Chemistry, Hanyang University, Ansan, Gyeonggi-do 15588, Republic of Korea
| |
Collapse
|
10
|
Tetrahydroquinoline-based tricyclic amines as potent and selective agonists of the 5-HT 2C receptor. Bioorg Med Chem Lett 2016; 26:5877-5882. [DOI: 10.1016/j.bmcl.2016.11.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2016] [Revised: 11/04/2016] [Accepted: 11/07/2016] [Indexed: 11/30/2022]
|
11
|
Bergström CAS, Charman WN, Porter CJH. Computational prediction of formulation strategies for beyond-rule-of-5 compounds. Adv Drug Deliv Rev 2016; 101:6-21. [PMID: 26928657 DOI: 10.1016/j.addr.2016.02.005] [Citation(s) in RCA: 106] [Impact Index Per Article: 13.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2015] [Revised: 02/11/2016] [Accepted: 02/17/2016] [Indexed: 12/12/2022]
Abstract
The physicochemical properties of some contemporary drug candidates are moving towards higher molecular weight, and coincidentally also higher lipophilicity in the quest for biological selectivity and specificity. These physicochemical properties move the compounds towards beyond rule-of-5 (B-r-o-5) chemical space and often result in lower water solubility. For such B-r-o-5 compounds non-traditional delivery strategies (i.e. those other than conventional tablet and capsule formulations) typically are required to achieve adequate exposure after oral administration. In this review, we present the current status of computational tools for prediction of intestinal drug absorption, models for prediction of the most suitable formulation strategies for B-r-o-5 compounds and models to obtain an enhanced understanding of the interplay between drug, formulation and physiological environment. In silico models are able to identify the likely molecular basis for low solubility in physiologically relevant fluids such as gastric and intestinal fluids. With this baseline information, a formulation scientist can, at an early stage, evaluate different orally administered, enabling formulation strategies. Recent computational models have emerged that predict glass-forming ability and crystallisation tendency and therefore the potential utility of amorphous solid dispersion formulations. Further, computational models of loading capacity in lipids, and therefore the potential for formulation as a lipid-based formulation, are now available. Whilst such tools are useful for rapid identification of suitable formulation strategies, they do not reveal drug localisation and molecular interaction patterns between drug and excipients. For the latter, Molecular Dynamics simulations provide an insight into the interplay between drug, formulation and intestinal fluid. These different computational approaches are reviewed. Additionally, we analyse the molecular requirements of different targets, since these can provide an early signal that enabling formulation strategies will be required. Based on the analysis we conclude that computational biopharmaceutical profiling can be used to identify where non-conventional gateways, such as prediction of 'formulate-ability' during lead optimisation and early development stages, are important and may ultimately increase the number of orally tractable contemporary targets.
Collapse
Affiliation(s)
- Christel A S Bergström
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia; Department of Pharmacy, Uppsala University, Uppsala Biomedical Center, P.O. Box 580, SE-751 23 Uppsala, Sweden.
| | - William N Charman
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| | - Christopher J H Porter
- Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia; ARC Centre of Excellence in Convergent Nano-Bio Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, Victoria 3052, Australia
| |
Collapse
|
12
|
Kleene R, Chaudhary H, Karl N, Katic J, Kotarska A, Guitart K, Loers G, Schachner M. Interaction between CHL1 and serotonin receptor 2c regulates signal transduction and behavior in mice. J Cell Sci 2015; 128:4642-52. [PMID: 26527397 DOI: 10.1242/jcs.176941] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Accepted: 10/28/2015] [Indexed: 02/05/2023] Open
Abstract
The serotonergic system plays important roles in multiple functions of the nervous system and its malfunctioning leads to neurological and psychiatric disorders. Here, we show that the cell adhesion molecule close homolog of L1 (CHL1), which has been linked to mental disorders, binds to a peptide stretch in the third intracellular loop of the serotonin 2c (5-HT2c) receptor through its intracellular domain. Moreover, we provide evidence that CHL1 deficiency in mice leads to 5-HT2c-receptor-related reduction in locomotor activity and reactivity to novelty, and that CHL1 regulates signaling pathways triggered by constitutively active isoforms of the 5-HT2c receptor. Furthermore, we found that the 5-HT2c receptor and CHL1 colocalize in striatal and hippocampal GABAergic neurons, and that 5-HT2c receptor phosphorylation and its association with phosphatase and tensin homolog (PTEN) and β-arrestin 2 is regulated by CHL1. Our results demonstrate that CHL1 regulates signal transduction pathways through constitutively active 5-HT2c receptor isoforms, thereby altering 5-HT2c receptor functions and implicating CHL1 as a new modulator of the serotonergic system.
Collapse
Affiliation(s)
- Ralf Kleene
- Zentrum für Molekulare Neurobiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - Harshita Chaudhary
- Zentrum für Molekulare Neurobiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - Nicole Karl
- Zentrum für Molekulare Neurobiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - Jelena Katic
- Zentrum für Molekulare Neurobiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - Agnieszka Kotarska
- Zentrum für Molekulare Neurobiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - Kathrin Guitart
- Zentrum für Molekulare Neurobiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - Gabriele Loers
- Zentrum für Molekulare Neurobiologie, Universitätsklinikum Hamburg-Eppendorf, Martinistr. 52, Hamburg 20246, Germany
| | - Melitta Schachner
- Keck Center for Collaborative Neuroscience and Department of Cell Biology and Neuroscience, Rutgers University, 604 Allison Road, Piscataway, NJ 08854, USA Center for Neuroscience, Shantou University Medical College, 22 Xin Ling Road, Shantou, Guangdong 515041, China
| |
Collapse
|
13
|
Cheng J, Kozikowski AP. We Need 2C but Not 2B: Developing Serotonin 2C (5-HT2C) Receptor Agonists for the Treatment of CNS Disorders. ChemMedChem 2015; 10:1963-7. [PMID: 26507582 PMCID: PMC4832415 DOI: 10.1002/cmdc.201500437] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2015] [Indexed: 01/16/2023]
Abstract
The serotonin 2C (5-HT2C ) receptor has been identified as a potential drug target for the treatment of a variety of central nervous system (CNS) disorders, such as obesity, substance abuse, and schizophrenia. In this Viewpoint article, recent progress in developing selective 5-HT2C agonists for use in treating these disorders is summarized, including the work of our group. Challenges in this field and the possible future directions are described. Homology modeling as a method to predict the binding modes of 5-HT2C ligands to the receptor is also discussed. Compared to known ligands, the improved pharmacological profiles of the 2-phenylcyclopropylmethylamine-based 5-HT2C agonists make them preferred candidates for further studies.
Collapse
Affiliation(s)
- Jianjun Cheng
- Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL, 60612, USA
| | - Alan P Kozikowski
- Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 South Wood Street, Chicago, IL, 60612, USA.
| |
Collapse
|
14
|
Yang Y, An S, Liu Y, Guo XX, Gao L, Wei JF, Xu TR. Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014). Expert Opin Ther Pat 2015; 26:89-106. [PMID: 26609882 DOI: 10.1517/13543776.2016.1113257] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/14/2023]
Abstract
INTRODUCTION Serotonin or 5-hydroxytryptamine (5-HT) is a substance found in plasma, which increases smooth muscle contraction and mediates platelet aggregation. In addition, it is a monoamine neurotransmitter and is implicated in diverse behaviors. The serotonin receptor 2 (5-HT2) subfamily is best known for biased signaling and is strongly expressed mainly in the brain regions postulated to be involved in the modulation of higher cognitive and affective functions. Modulators of the 5-HT2 receptor are currently used to treat a variety of diseases including chronic pain and psychonosema. These properties suggest that 5-HT2 receptors may become an important therapeutic target for the treatment of various pathological conditions. AREAS COVERED This review highlights the significant progress that has been made in the discovery and development of 5-HT2 receptor agonists and antagonists based on an analysis of the patent literature between January 2004 and December 2014. EXPERT OPINION Cumulative evidence over the past decade supports the notion that the modulation of 5-HT2 receptors has a positive effect on human cognition and emotion. Therefore, we suggest that new agonists and antagonists may play an important role in the treatment of disorders such as schizophrenia, addiction and obesity.
Collapse
Affiliation(s)
- Yang Yang
- a Faculty of Life Science and Technology , Kunming University of Science and Technology , Kunming , Yunnan 650500 , China
| | - Shu An
- a Faculty of Life Science and Technology , Kunming University of Science and Technology , Kunming , Yunnan 650500 , China
| | - Ying Liu
- a Faculty of Life Science and Technology , Kunming University of Science and Technology , Kunming , Yunnan 650500 , China
| | - Xiao-Xi Guo
- a Faculty of Life Science and Technology , Kunming University of Science and Technology , Kunming , Yunnan 650500 , China
| | - Linghuan Gao
- a Faculty of Life Science and Technology , Kunming University of Science and Technology , Kunming , Yunnan 650500 , China
| | - Ji-Fu Wei
- b Research Division of Clinical Pharmacology , The First Affiliated Hospital with Nanjing Medical University , 300 Guangzhou Road, Nanjing 210029 , China
| | - Tian-Rui Xu
- a Faculty of Life Science and Technology , Kunming University of Science and Technology , Kunming , Yunnan 650500 , China
| |
Collapse
|
15
|
Higgins GA, Fletcher PJ. Therapeutic Potential of 5-HT2C Receptor Agonists for Addictive Disorders. ACS Chem Neurosci 2015; 6:1071-88. [PMID: 25870913 DOI: 10.1021/acschemneuro.5b00025] [Citation(s) in RCA: 64] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2023] Open
Abstract
The neurotransmitter 5-hydroxytryptamine (5-HT; serotonin) has long been associated with the control of a variety of motivated behaviors, including feeding. Much of the evidence linking 5-HT and feeding behavior was obtained from studies of the effects of the 5-HT releaser (dex)fenfluramine in laboratory animals and humans. Recently, the selective 5-HT2C receptor agonist lorcaserin received FDA approval for the treatment of obesity. This review examines evidence to support the use of selective 5-HT2C receptor agonists as treatments for conditions beyond obesity, including substance abuse (particularly nicotine, psychostimulant, and alcohol dependence), obsessive compulsive, and excessive gambling disorder. Following a brief survey of the early literature supporting a role for 5-HT in modulating food and drug reinforcement, we propose that intrinsic differences between SSRI and serotonin releasers may have underestimated the value of serotonin-based pharmacotherapeutics to treat clinical forms of addictive behavior beyond obesity. We then highlight the critical involvement of the 5-HT2C receptor in mediating the effect of (dex)fenfluramine on feeding and body weight gain and the evidence that 5-HT2C receptor agonists reduce measures of drug reward and impulsivity. A recent report of lorcaserin efficacy in a smoking cessation trial further strengthens the idea that 5-HT2C receptor agonists may have potential as a treatment for addiction. This review was prepared as a contribution to the proceedings of the 11th International Society for Serotonin Research Meeting held in Hermanus, South Africa, July 9-12, 2014.
Collapse
Affiliation(s)
- Guy A. Higgins
- InterVivo Solutions Inc., 120 Carlton Street, Toronto, ON M5A
4K2, Canada
- Department of Pharmacology & Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada
| | - Paul J. Fletcher
- Section of Biopsychology
and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T 1R8, Canada
- Departments of Psychiatry & Psychology, University of Toronto, Toronto, ON M5T 1R8, Canada
| |
Collapse
|
16
|
Cheng J, Giguère PM, Onajole OK, Lv W, Gaisin A, Gunosewoyo H, Schmerberg CM, Pogorelov VM, Rodriguiz RM, Vistoli G, Wetsel WC, Roth BL, Kozikowski AP. Optimization of 2-phenylcyclopropylmethylamines as selective serotonin 2C receptor agonists and their evaluation as potential antipsychotic agents. J Med Chem 2015; 58:1992-2002. [PMID: 25633969 DOI: 10.1021/jm5019274] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
The discovery of a new series of compounds that are potent, selective 5-HT2C receptor agonists is described herein as we continue our efforts to optimize the 2-phenylcyclopropylmethylamine scaffold. Modifications focused on the alkoxyl substituent present on the aromatic ring led to the identification of improved ligands with better potency at the 5-HT2C receptor and excellent selectivity against the 5-HT2A and 5-HT2B receptors. ADMET studies coupled with a behavioral test using the amphetamine-induced hyperactivity model identified four compounds possessing drug-like profiles and having antipsychotic properties. Compound (+)-16b, which displayed an EC50 of 4.2 nM at 5-HT2C, no activity at 5-HT2B, and an 89-fold selectivity against 5-HT2A, is one of the most potent and selective 5-HT2C agonists reported to date. The likely binding mode of this series of compounds to the 5-HT2C receptor was also investigated in a modeling study, using optimized models incorporating the structures of β2-adrenergic receptor and 5-HT2B receptor.
Collapse
Affiliation(s)
- Jianjun Cheng
- Drug Discovery Program, Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago , 833 South Wood Street, Chicago, Illinois 60612, United States
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Shidore M, Machhi J, Murumkar P, Barmade M, Thanki J, Yadav MR. 3-Substituted 1-methyl-3-benzazepin-2-ones as 5-HT2C receptor agonists. RSC Adv 2015. [DOI: 10.1039/c5ra17718a] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
In search of potent and selective 5-HT2C receptor agonists, a series of novel 3-substituted 1-methyl-3-benzazepin-2-ones and 8-chloro-1-methyl-3-benzazepin-2-ones have been synthesized and evaluated for their 5-HT2C receptor agonistic potential.
Collapse
Affiliation(s)
- Mahesh Shidore
- Pharmacy Department
- Faculty of Technology & Engineering, Kalabhavan
- The M. S. University of Baroda
- Vadodara-390 001
- India
| | - Jatin Machhi
- Pharmacy Department
- Faculty of Technology & Engineering, Kalabhavan
- The M. S. University of Baroda
- Vadodara-390 001
- India
| | - Prashant Murumkar
- Pharmacy Department
- Faculty of Technology & Engineering, Kalabhavan
- The M. S. University of Baroda
- Vadodara-390 001
- India
| | - Mahesh Barmade
- Pharmacy Department
- Faculty of Technology & Engineering, Kalabhavan
- The M. S. University of Baroda
- Vadodara-390 001
- India
| | - Jigar Thanki
- Pharmacy Department
- Faculty of Technology & Engineering, Kalabhavan
- The M. S. University of Baroda
- Vadodara-390 001
- India
| | - Mange Ram Yadav
- Pharmacy Department
- Faculty of Technology & Engineering, Kalabhavan
- The M. S. University of Baroda
- Vadodara-390 001
- India
| |
Collapse
|
18
|
Storer RI, Brennan PE, Brown AD, Bungay PJ, Conlon KM, Corbett MS, DePianta RP, Fish PV, Heifetz A, Ho DKH, Jessiman AS, McMurray G, de Oliveira CAF, Roberts LR, Root JA, Shanmugasundaram V, Shapiro MJ, Skerten M, Westbrook D, Wheeler S, Whitlock GA, Wright J. Multiparameter Optimization in CNS Drug Discovery: Design of Pyrimido[4,5-d]azepines as Potent 5-Hydroxytryptamine 2C (5-HT2C) Receptor Agonists with Exquisite Functional Selectivity over 5-HT2A and 5-HT2B Receptors. J Med Chem 2014; 57:5258-69. [DOI: 10.1021/jm5003292] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Affiliation(s)
| | | | | | | | | | - Matthew S. Corbett
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | - Robert P. DePianta
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | | | - Alexander Heifetz
- Evotec (UK) Ltd., 114 Innovation
Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ, United Kingdom
| | | | | | | | | | | | | | | | - Michael J. Shapiro
- Pfizer Worldwide Research and Development, Eastern Point Road, Groton, Connecticut 06340, United States
| | | | | | | | | | | |
Collapse
|
19
|
Higgins GA, Sellers EM, Fletcher PJ. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. Trends Pharmacol Sci 2013; 34:560-70. [PMID: 24041919 DOI: 10.1016/j.tips.2013.08.001] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2013] [Revised: 07/26/2013] [Accepted: 08/02/2013] [Indexed: 12/25/2022]
Abstract
The recent US Food and Drug Administration (FDA) approval of the serotonin (5-hydroxytryptamine, 5-HT) 5-HT2C receptor agonist lorcaserin for the treatment of obesity represents a new therapeutic drug class available to the clinic. Preclinical evidence supports the potential for this drug class to treat other related conditions such as substance abuse. In the present article we review this evidence and further suggest that overlapping neurobiological systems may contribute to an anti-addictive and anti-obesity profile. The availability of selective 5-HT2C agonists provides an opportunity to evaluate their potential as treatments for nicotine dependence or psychostimulant abuse, conditions for which there is significant medical need but only limited available treatment options.
Collapse
Affiliation(s)
- Guy A Higgins
- InterVivo Solutions Inc, 120 Carlton Street, Toronto, ON M5A 4K2, Canada; Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON M5S 1A8, Canada.
| | | | | |
Collapse
|
20
|
Manvich DF, Kimmel HL, Cooper DA, Howell LL. The serotonin 2C receptor antagonist SB 242084 exhibits abuse-related effects typical of stimulants in squirrel monkeys. J Pharmacol Exp Ther 2012; 342:761-9. [PMID: 22685342 DOI: 10.1124/jpet.112.195156] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Antagonists of the serotonin (5-hydroxytryptamine; 5-HT) type 2C receptor (5-HT(2C)R) are being considered as potential pharmacotherapeutics for various affective disorders, but evidence suggests that these compounds enhance the effects of cocaine and related psychostimulants in rodents. However, the effects of selective 5-HT(2C)R antagonists have not been evaluated in nonhuman primates. The present studies used operant-behavioral and in vivo microdialysis techniques to assess the impact of 5-HT(2C)R antagonism on the behavioral and neurochemical effects of cocaine in squirrel monkeys. In subjects trained to lever-press on a fixed-interval schedule of stimulus termination, pretreatment with the highly selective 5-HT(2C)R antagonist 6-chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1H-indole-1-carboxyamide dihydrochloride (SB 242084) (vehicle, 0.01-0.1 mg/kg) produced behavioral-stimulant effects alone and interacted with cocaine in an apparently additive manner. In monkeys trained to self-administer intravenous cocaine according to a second-order schedule of drug delivery, SB 242084 (vehicle, 0.03-0.1 mg/kg) modulated cocaine-induced reinstatement of previously extinguished responding and maintained self-administration behavior when substituted for cocaine availability. These studies are the first to assess the direct reinforcing effects of a 5-HT(2C)R-selective antagonist in any species. Finally, in vivo microdialysis studies revealed that pretreatment with SB 242084 (0.1 mg/kg) modulated cocaine-induced dopamine increases within the nucleus accumbens, but not the caudate nucleus, of awake subjects. Taken together, the results suggest that SB 242084 exhibits a behavioral profile that is qualitatively similar to other psychostimulants, although its efficacy is modest compared with cocaine. The observed interactions with cocaine and the substitution for cocaine self-administration may be indicative of some degree of abuse potential in humans.
Collapse
Affiliation(s)
- Daniel F Manvich
- Yerkes National Primate Research Center, Emory University, Atlanta, GA, USA
| | | | | | | |
Collapse
|
21
|
Schneider H, Fritzky L, Williams J, Heumann C, Yochum M, Pattar K, Noppert G, Mock V, Hawley E. Cloning and expression of a zebrafish 5-HT(2C) receptor gene. Gene 2012; 502:108-17. [PMID: 22521866 DOI: 10.1016/j.gene.2012.03.070] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2011] [Revised: 03/23/2012] [Accepted: 03/28/2012] [Indexed: 11/18/2022]
Abstract
The 5-HT(2C) receptor is one of 14 different serotonin (5-HT) receptors that control neural function and behavior. Here, we present the entire sequence of a zebrafish 5-HT(2C) receptor cDNA including the 3' untranslated region and the previously unknown 5' untranslated region. The cloned 5-HT(2C) receptor gene is located on chromosome 7, is approximately 202 kbp long, and contains six exons. The coding region of the gene is 1557 bp long and flanked by a 504 bp 5' UTR and a 1474 bp 3' UTR. The deduced protein sequence of 518 amino acids aligns with orthologs of other vertebrates and is 54% identical to the human and mouse 5-HT(2C) receptor protein sequences. The region of the cDNA that encodes the 2nd cytoplasmic loop of the protein shows a 66% identity with vertebrate orthologs and clearly identifies the gene as a 5-HT(2C) receptor gene. Coupling sites for beta-arrestin and calmodulin are conserved in zebrafish. In-situ hybridization shows that the receptor is expressed in the brain and spinal cord including areas such as the olfactory bulb, the dorsal thalamus, the posterior tuberculum, the hypothalamus and the medulla oblongata. Reverse Transcriptase-PCR experiments indicate that the receptor gene can also be active in other tissues such as skin, ovaries, and axial muscle of adult zebrafish. Expression of the 5-HT(2C) receptor during ontogeny was found as early as 2.5 hpf. Five edited adenines in the region of the human, rat and mouse mRNA that encodes the 2nd cytoplasmic loop are conserved in the zebrafish transcript. However, RNA editing was not detected in the zebrafish. The results characterize the zebrafish 5-HT(2C) receptor gene and gene expression pattern for the first time. The similarities to mammalian 5-HT(2C) receptor genes suggest the use of zebrafish for the study of 5-HT(2C) receptor function in behavior, development and drug discovery.
Collapse
Affiliation(s)
- Henning Schneider
- DePauw University, Department of Biology, Greencastle, IN 46135, USA.
| | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Pharmacological and genetic interventions in serotonin (5-HT)(2C) receptors to alter drug abuse and dependence processes. Brain Res 2012; 1476:132-53. [PMID: 22494568 DOI: 10.1016/j.brainres.2012.03.035] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2012] [Revised: 03/13/2012] [Accepted: 03/15/2012] [Indexed: 11/22/2022]
Abstract
The present review provides an overview on serotonin (5-hydroxytryptamine; 5-HT)(2C) receptors and their relationship to drug dependence. We have focused our discussion on the impact of 5-HT(2C) receptors on the effects of different classes of addictive drugs, illustrated by reference to data using pharmacological and genetic tools. The neurochemical mechanism of the interaction between 5-HT(2C) receptors, with focus on the mesocorticolimbic dopaminergic system, and drugs of abuse (using cocaine as an example) is discussed. Finally, we integrate recent nonclinical and clinical research and information with marketed products possessing 5-HT(2C) receptor binding affinities. Accordingly, available nonclinical data and some clinical observations targeting 5-HT(2C) receptors may offer innovative translational strategies for combating drug dependence.This article is part of a Special Issue entitled: Brain Integration.
Collapse
|
23
|
Kamata M, Yamashita T, Imaeda T, Tanaka T, Masada S, Kamaura M, Kasai S, Hara R, Sasaki S, Takekawa S, Asami A, Kaisho T, Suzuki N, Ashina S, Ogino H, Nakano Y, Nagisa Y, Kato K, Kato K, Ishihara Y. Melanin-Concentrating Hormone Receptor 1 Antagonists. Synthesis and Structure–Activity Relationships of Novel 3-(Aminomethyl)quinolines. J Med Chem 2012; 55:2353-66. [DOI: 10.1021/jm201596h] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Makoto Kamata
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Toshiro Yamashita
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Toshihiro Imaeda
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Toshio Tanaka
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shinichi Masada
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Masahiro Kamaura
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shizuo Kasai
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Ryoma Hara
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shigekazu Sasaki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shiro Takekawa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Asano Asami
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Tomoko Kaisho
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Nobuhiro Suzuki
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Shuntaro Ashina
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Hitomi Ogino
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yoshihide Nakano
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yasutaka Nagisa
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Koki Kato
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Kaneyoshi Kato
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| | - Yuji Ishihara
- Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, 26-1 Muraokahigashi,
2-Chome, Fujisawa, Kanagawa 251-8555, Japan
| |
Collapse
|
24
|
Chen G, Cho SJ, Huang XP, Jensen NH, Svennebring A, Sassano MF, Roth BL, Kozikowski AP. Rational Drug Design Leading to the Identification of a Potent 5-HT(2C) Agonist Lacking 5-HT(2B) Activity. ACS Med Chem Lett 2011; 2:929-932. [PMID: 22778800 DOI: 10.1021/ml200206z] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
The 5-HT(2C) receptor is an attractive drug target in the quest for new therapeutics to treat a variety of human disorders. We have previously undertaken a structural optimization campaign that has led to some potent and moderately selective 5-HT(2C) receptor agonists. After expanding our structure-function library, we were able to combine our datasets so as to allow the design of compounds of improved selectivity and potency. We disclose herein the structural optimization of our previously reported 5-HT(2B)/5-HT(2C) agonists, which has led to the identification of a highly selective 5-HT(2C) agonist, (+)-trans-[2-(2-cyclopropylmethoxyphenyl)cyclopropyl]methylamine hydrochloride, with an EC(50) of 55 nM and no detectable agonism at the 5-HT(2B) receptor.
Collapse
Affiliation(s)
- Gang Chen
- Drug Discovery Program, Department
of Medicinal Chemistry and Pharmacognosy, College of Pharmacy (M/C781), University of Illinois at Chicago, 833 South Wood Street,
Chicago, Illinois 60612-7230, United States
| | - Sung Jin Cho
- Drug Discovery Program, Department
of Medicinal Chemistry and Pharmacognosy, College of Pharmacy (M/C781), University of Illinois at Chicago, 833 South Wood Street,
Chicago, Illinois 60612-7230, United States
| | - Xi-Ping Huang
- Department of Pharmacology,
Psychiatry, Comprehensive Cancer Center, Center for Neurobiology,
Division of NIMH Psychoactive Drug Screening Program, University of North Carolina Medical School, Chapel
Hill, CB # 7365, North Carolina 27599, United States
| | - Niels H. Jensen
- Department of Pharmacology,
Psychiatry, Comprehensive Cancer Center, Center for Neurobiology,
Division of NIMH Psychoactive Drug Screening Program, University of North Carolina Medical School, Chapel
Hill, CB # 7365, North Carolina 27599, United States
| | - Andreas Svennebring
- Drug Discovery Program, Department
of Medicinal Chemistry and Pharmacognosy, College of Pharmacy (M/C781), University of Illinois at Chicago, 833 South Wood Street,
Chicago, Illinois 60612-7230, United States
| | - Maria F. Sassano
- Department of Pharmacology,
Psychiatry, Comprehensive Cancer Center, Center for Neurobiology,
Division of NIMH Psychoactive Drug Screening Program, University of North Carolina Medical School, Chapel
Hill, CB # 7365, North Carolina 27599, United States
| | - Bryan L. Roth
- Department of Pharmacology,
Psychiatry, Comprehensive Cancer Center, Center for Neurobiology,
Division of NIMH Psychoactive Drug Screening Program, University of North Carolina Medical School, Chapel
Hill, CB # 7365, North Carolina 27599, United States
| | - Alan P. Kozikowski
- Drug Discovery Program, Department
of Medicinal Chemistry and Pharmacognosy, College of Pharmacy (M/C781), University of Illinois at Chicago, 833 South Wood Street,
Chicago, Illinois 60612-7230, United States
| |
Collapse
|
25
|
Tye H, Mueller SG, Prestle J, Scheuerer S, Schindler M, Nosse B, Prevost N, Brown CJ, Heifetz A, Moeller C, Pedret-Dunn A, Whittaker M. Novel 6,7,8,9-tetrahydro-5H-1,4,7,10a-tetraaza-cyclohepta[f]indene analogues as potent and selective 5-HT(2C) agonists for the treatment of metabolic disorders. Bioorg Med Chem Lett 2010; 21:34-7. [PMID: 21146986 DOI: 10.1016/j.bmcl.2010.11.089] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2010] [Revised: 11/17/2010] [Accepted: 11/18/2010] [Indexed: 11/30/2022]
Abstract
The discovery of a novel series of 5-HT(2C) agonists based on a tricyclic pyrazolopyrimidine scaffold is described. Compounds with good levels of in vitro potency and moderate to good levels of selectivity with respect to the 5-HT(2A) and 5-HT(2B) receptors were identified. One of the analogues (7 g) was found to be efficacious in a sub-chronic weight loss model. A key limitation of the series of compounds was that they were found to be potent inhibitors of the hERG ion channel. Some compounds, bearing polar side chains were identified which showed a much reduced hERG liability however these compounds were sub-optimal in terms of their in vitro potency or selectivity.
Collapse
Affiliation(s)
- Heather Tye
- Evotec UK Ltd, 114 Milton Park, Abingdon, Oxfordshire OX14 4SA, UK.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|